Connecting prognostic Ligand receptor signaling loops in advanced ovarian cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Eng, Kevin H ^a   Ruggeri, Christina ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 1 A1; CYTOKINE; HERMES ANTIGEN; LIGAND RECEPTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; AUTOCRINE EFFECT; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS LINKING; ENDOCRINE SYSTEM; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; HEALTH SURVEY; HUMAN; LIGAND RECEPTOR PAIR; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; NORMAL DISTRIBUTION; NUCLEIC ACID DATABASE; OVARY CANCER; OVARY CARCINOMA; POSITIVE FEEDBACK; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SIGNAL TRANSDUCTION; SURVIVAL TIME; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENETICS; MORTALITY; OVARIAN NEOPLASMS; PHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; THEORETICAL MODEL;

DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MODELS, THEORETICAL; OVARIAN NEOPLASMS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84907221071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107193     Document Type: Article

References (19)

1. Graeber TG, Eisenberg D (2001) Bioinformatic identification of potential autocrine signaling loops in cancers from gene expression profiles. Nature Genetics 29: 295-300.
2. Castellano G, Reid JF, Alberti P, Carcangiu ML, Tomassetti A, et al. (2006) New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies. Cancer Research 66: 10709-10719.
3. Shedden K, Taylor J (2005) Differential correlation detects complex associations between gene expression and clinical outcomes in lung adenocarcinomas. In: Methods of Microarray Data Analysis, Springer. pp. 121-131.
4. Schäfer J, Strimmer K (2005) An empirical bayes approach to inferring largescale gene association networks. Bioinformatics 21: 754-764.
5. Zhao SD, Cai TT, Li H (2014) Direct estimation of differential networks. Biometrika in press.
6. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M (2012) KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Research 40: D109-D114.
7. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
8. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research 14: 5198-5208.
9. Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, et al. (2012) High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clinical Cancer Research 18: 1374-1385.
10. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cellular signalling 19: 2013-2023.
11. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of affymetrix genechip probe level data. Nucleic acids research 31: e15-e15.
12. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer 11: 719-725.
13. Best DJ, Roberts DE (1975) Algorithm AS89: The upper tail probabilities of Spearman's r. Applied Statistics 24: 377-379.
14. Eng KH, Hanlon BM (2014) Discrete mixture regression models for heterogenous time-to-event data: Cox assisted clustering. Bioinformatics 30: 1690-1697.
15. Nowak AK, Robinson BW, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response implications for combination chemoimmunotherapy. Cancer research 62: 2353-2358.
16. Trojandt S, Knies D, Pektor S, Ritz S, Mailänder V, et al. (2013) The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells. Cancer Immunology, Immunotherapy 62: 1315-1326.
17. Yap TA, Carden CP, Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer 9: 167-181.
18. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine 365: 2473-2483.
19. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral t cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 348: 203-213.